Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
IORT on Borderline Resectable Pancreatic Cancer

This phase II study investigates the efficacy of IORT for patients with borderline resectable pancreatic cancer. The purpose of the study is to investigate whether the addition of IORT, after

  • 0 views
  • 15 Apr, 2020
  • 1 location
Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1

This study is to investigate whether neoadjuvant chemotherapy plus SBRT results in better outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of gemcitabine plus nab-paclitaxel with SBRT and S-1 plus nab-paclitaxel with SBRT.

adenocarcinoma
chemoradiotherapy
pancreatic adenocarcinoma
resectable pancreatic cancer
stereotactic body radiation therapy
  • 0 views
  • 17 Nov, 2019
  • 1 location
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Using alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil (5FU) and folinic acid (Leucovorin) regimens of localized cancer, we hope to ensure exposure of the cancer to a broader array of potentially active agents. Also, potentially improves patient tolerance and minimizes significant drug toxicity that could impair delivery of all treatment …

irinotecan
platelet count
resectable pancreatic cancer
gemcitabine
paclitaxel
  • 3 views
  • 21 Jan, 2020
  • 1 location
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

borderline resectable pancreatic cancer. A total of 60 subjects who meet the criteria will receive neoadjuvant chemotherapy of nab-paclitaxel and S-1, for a maximum of 4 cycles prior to pancreatectomy. The

  • 0 views
  • 16 Mar, 2020
  • 1 location
A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

pancreatic cancer. Subjects will take MRx0518 daily for one week prior to the start of radiation therapy, throughout radiation and until surgical resection of the tumour.

adenocarcinoma
paclitaxel
neutrophil count
pancreatic adenocarcinoma
platelet count
  • 0 views
  • 06 Jan, 2020
  • 1 location
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

treatment in resectable or borderline resectable pancreatic cancer is feasible and efficacious. The combination of Durvalumab with cytotoxic chemotherapy (gemcitabine) as an adjuvant treatment is

corticosteroids
immunostimulant
celiac
resectable pancreatic cancer
solid tumour
  • 3 views
  • 08 Nov, 2020
  • 1 location
A Study of Nal-IRI With 5-FU Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer

aggressive biologic behavior, an increasing interest is growing about preoperative treatments in resectable pancreatic cancer. The combination chemotherapeutic regimen with irinotecan + 5

folfirinox
irinotecan
celiac
resectable pancreatic cancer
cancer
  • 3 views
  • 08 Nov, 2020
  • 1 location
Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer

Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximum number of tumor infiltrating T-cells.

  • 3 views
  • 08 Nov, 2020
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer

Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases. To date, there are few biomarkers in circulating blood as prognostic or diagnostic markers in pancreatic cancer. The …

  • 4 views
  • 30 Aug, 2020
  • 1 location
GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma

pancreas cancer. Data from this study would likely inform future studies where patients are given personalised options for the best treatment strategies rather than one empiric approach.

  • 0 views
  • 10 Sep, 2020
  • 1 location